So, over the past 2 decades, scientists have changed how they think about treatment for major depressive disorder as their understanding of the brain biology behind depression has changed.

Credit: Getty Images. Exxua is expected to be available in early 2024. The Food and Drug Administration (FDA) has approved Exxua ™ (gepirone hydrochloride extended-release tablets) for the ...

for Exxua ™ (gepirone hydrochloride extended-release [ER]) for the treatment of major depressive disorder (MDD). Exxua (formerly known as Travivo) is a novel oral serotonin (5HT) 1A receptor ...

If you have been diagnosed with major depressive disorder, you’ll want to get treatment as soon as possible. To get the care you need, it’s important you find a specialist that fits your needs.

Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.

Data suggests that more than 8.3% of U.S. adults experienced a major depressive episode in 2021. Some people with MDD never get treatment. However, most people with the disorder can learn to cope ...

Leslie Citrome, MD, MPH, looks back at how major depressive disorder (MDD ... As a part of the increasingly complex treatment landscape, Dr Citrome notes the challenges presented by patients ...

The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and other ...

But recent findings estimate that these drugs don’t work for as many as 55 percent of people with major depressive disorder (MDD ... antidepressant treatment. Research shows NMDA receptor ...

Mona Chitre, PharmD, CGP: There are health care disparities in major depressive disorder. We absolutely see them come through in our data as well as in national publications. One in every 2 ...

a 10-question diagnostic questionnaire used by mental-health professionals to measure the severity of depressive symptoms. The treatment also failed to meet a secondary endpoint of change from ...